RT Journal Article
SR Electronic
T1 Phylogenetic-based inference reveals distinct transmission dynamics of SARS-CoV-2 variant of concern Gamma and lineage P.2 in Brazil
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.24.21265116
DO 10.1101/2021.10.24.21265116
A1 Tiago Graf
A1 Gonzalo Bello
A1 Felipe Gomes Naveca
A1 Marcelo Gomes
A1 Vanessa Leiko Oikawa Cardoso
A1 Alexandre Freitas da Silva
A1 Filipe Zimmer Dezordi
A1 Mirleide Cordeiro dos Santos
A1 Katia Correa de Oliveira Santos
A1 Erika Lopes Rocha Batista
A1 Alessandro Leonardo alvares Magalhaes
A1 Fernando Vinhal
A1 Brazilian Ministry of Health COVID-19 Genomic Surveillance Network
A1 Fabio Miyajima
A1 Helisson Faoro
A1 Ricardo Khouri
A1 Gabriel Luz Wallau
A1 Edson Delatorre
A1 Marilda Mendonca Siqueira
A1 Paola Cristina Resende
YR 2021
UL http://medrxiv.org/content/early/2021/11/09/2021.10.24.21265116.abstract
AB The COVID-19 epidemic in Brazil experienced two major country-wide lineage replacements, the first driven by the lineage P.2, formerly classified as variant of interest (VOI) Zeta in late 2020 and the second by the variant of concern (VOC) Gamma in early 2021. To better understand how these SARS-CoV-2 lineage turnovers occurred in Brazil, we analyzed 11,724 high-quality SARS-CoV-2 whole genomes of samples collected in different country regions between September 2020 and April 2021. Our findings indicate that the spatial dispersion of both variants in Brazil was driven by short and long-distance viral transmission. The lineage P.2 harboring Spike mutation E484K probably emerged around late July 2020 in the Rio de Janeiro (RJ) state, which contributed with most (∼50%) inter-state viral disseminations, and only became locally established in most Brazilian states by October 2020. The VOC Gamma probably arose in November 2020 in the Amazonas (AM) state, which was responsible for 60-70% of the inter-state viral dissemination, and the earliest timing of community transmission of this VOC in many Brazilian states was already traced to December 2020. We estimate that variant Gamma was 1.56-3.06 more transmissible than variant P.2 co-circulating in RJ and that the median effective reproductive number (Re) of Gamma in RJ and SP states (Re = 1.59-1.91) was lower than in AM (Re = 3.55). In summary, although the epicenter of the lineage P.2 dissemination in Brazil was the heavily interconnected Southeastern region, it displayed a slower rate of spatial spread than the VOC Gamma originated in the more isolated Northern Brazilian region. Our findings also support that the VOC Gamma was more transmissible than lineage P.2, although the viral Re of the VOC varied according to the geographic context.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFinancial support was provided by Fundacao de Amparo a Pesquisa do Estado do Amazonas (FAPEAM) (PCTI-EmergeSaude/AM call 005/2020 and Rede Genomica de Vigilancia em Saude-REGESAM); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) (grant 402457/2020-0); CNPq/Ministerio da Ciencia, Tecnologia, Inovacoes e Comunicacoes/Ministerio da Saude (MS/FNDCT/SCTIE/Decit) (grant 403276/2020-9); Departamento da Ciencia e Tecnologia (DECIT), Ministerio da Saude; Inova Fiocruz/Fundacao Oswaldo Cruz (Grants VPPCB-007-FIO-18-2-30 and VPPCB-005-FIO-20-2-87), INCT-FCx (465259/2014-6) and Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ) (26/210.196/2020). F.G.N, G.L.W, G.B and M.M.S are supported by the CNPq through their productivity research fellowships (306146/2017-7, 303902/2019-1, 302317/2017-1 and 313403/2018-0, respectively). G.B. is also funded by FAPERJ (Grant number E-26/202.896/2018).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study involves only openly available human data, which can be obtained from EpiCov Database in GISAID (https://www.gisaid.org/)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at the EpiCoV database in GISAID (https://www.gisaid.org/)